قارن الطرق
راجع الطرق التي اخترتها جنبًا إلى جنب؛ الصفوف المختلفة مميَّزة.
| تجربة سريرية استعادية من المرحلة الثانية× | تجربة سريرية للمرحلة الأولى× | |
|---|---|---|
| المجال | علم الأوبئة | علم الأوبئة |
| العائلة | Process / pipeline | Process / pipeline |
| سنة النشأة≠ | 1980s–1990s (with growth in oncology retrospective analyses) | 1960s (formal regulatory framework established ~1963–1970s) |
| صاحب الطريقة≠ | Adapted from standard Phase II trial methodology; retrospective variant formalized in oncology practice | Regulatory and clinical pharmacology community; formalized in U.S. FDA IND regulations (1963) and ICH guidelines |
| النوع≠ | Observational retrospective study | Interventional clinical study design |
| المصدر التأسيسي≠ | Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10(1), 1–10. DOI ↗ | Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. DOI ↗ |
| الأسماء البديلة | retrospective Phase II study, historical Phase II analysis, retrospective efficacy study, Phase II retrospective analysis | Phase 1 trial, first-in-human study, FIH study, dose-escalation study |
| ذات صلة≠ | 5 | 6 |
| الملخص≠ | A retrospective Phase II clinical trial evaluates a treatment's preliminary efficacy and safety signals using existing archival data — medical records, registries, or electronic health records — rather than prospectively enrolling new patients. It mirrors the objectives of a standard Phase II trial (estimating response rate, tolerability, and early efficacy) but does so by looking backward at patients who have already received the intervention, making it faster and less costly than a prospective design. | A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials. |
| ScholarGateمجموعة البيانات ↗ |
|
|